RGEN - Repligen Exits Third Quarter Armed With a $500 Million War Chest
After an eventful first half of the year, Repligen (NASDAQ: RGEN) turned in a relatively ho-hum performance in the third quarter. To be fair, revenue grew 40% year over year and the company raised full-year 2019 revenue guidance, but investors have come to expect that from the bioprocessing leader. It has been one of the best growth stocks on the market in recent years, after all.
Not much else stood out for the business, but that shouldn't be confused with a lack of progress. Repligen made progress integrating its largest acquisition ever, C Technologies, and still managed to end September with a record $513 million in cash. Considering that the company has been built on acquisitions, shareholders can't discount the possibility that another could be on the way. Here's what investors need to know about Repligen's latest operating results.
Image source: Getty Images.